Latest ebit for ABL.DE: $7.2B, below the Healthcare sector average of $1.1T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Abbott Laboratories (ABL.DE) currently reports a EBIT of $7.2B as of September 2026. That compares with $8.4B in the prior-year period — down 14.6% year over year. That is below the Healthcare sector average of $1.1T. Use the charts on this page to explore Abbott Laboratories's EBIT history and peer comparisons.
Abbott Laboratories's EBIT decreased from $8.4B to $7.2B — a 14.6% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Abbott Laboratories's EBIT of $7.2B is lower than the Healthcare sector average of $1.1T. That is roughly 99.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Abbott Laboratories reported $7.2B in EBIT as of September 2026. That compares with $8.4B in the prior-year period — down 14.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $7.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.1T. From there, open related valuation or income-statement pages for Abbott Laboratories, and consider following ABL.DE for alerts when major investors trade the stock.